Idelle Labs Faces FDA Recall for Undeclared Active Ingredient in SURE Antiperspirant
Idelle Labs initiated a Class III recall for SURE 48 hr Confidence Unscented invisible solid Anti-Perspirant & Deodorant due to an undeclared active ingredient. The FDA-terminated recall, D-0783-2020, highlights critical labeling and quality control failures. This event underscores the imperative for robust supplier qualification and rigorous internal verification processes for all chemical and life science product distributors.
FDA Findings: Undeclared Active Ingredient Triggers Idelle Labs Recall
On November 20, 2019, Idelle Labs, headquartered in El Paso, TX, initiated a Class III voluntary recall, designated D-0783-2020, for its SURE 48 hr Confidence Unscented invisible solid Anti-Perspirant & Deodorant. The critical regulatory breach identified was the presence of an undeclared active ingredient, meaning the active compound listed on the product label was not the actual active ingredient contained within the product. This fundamental misrepresentation impacts product efficacy and consumer safety, even if the health risk is deemed remote. The affected product, with NDC# 41595-5509-2 and UPC 8 83484 71717 2, was distributed nationwide across the USA. Specific lots identified in the recall included 19273K1, 19274K1, 19274K2, 19725K1, 19725K2, and 19726K1. For procurement directors, this event underscores the absolute necessity of rigorous incoming material verification and finished product testing, particularly for consumer health products where labeling accuracy is paramount. Regulatory affairs teams must ensure that all product specifications, including active ingredient declarations, are meticulously cross-referenced against analytical results to prevent such costly and reputation-damaging discrepancies.
Regulatory Implications of Labeling Discrepancies for Distributed Products
The Class III classification of this recall, while indicating a remote probability of adverse health consequences, does not diminish the severity of the regulatory violation. An undeclared active ingredient represents a significant failure in quality control and regulatory compliance. Idelle Labs, as the distributor based in El Paso, TX, bears the ultimate responsibility for ensuring the products it places on the market are accurately labeled and meet all regulatory requirements, irrespective of the product being 'Made in Canada.' This incident highlights the inherent risks in complex international supply chains where manufacturing and distribution responsibilities are bifurcated. The recall was initiated on November 20, 2019, classified by the FDA on January 16, 2020, and ultimately terminated on September 28, 2022. This nearly three-year duration for resolution indicates a substantial logistical and administrative burden on Idelle Labs to manage the recall process effectively. Supply chain VPs must recognize that robust contractual agreements with third-party manufacturers are insufficient without parallel, independent verification processes. Business development executives should factor the potential for such extensive recall timelines and associated costs into their risk assessments for new product introductions and market expansions.
Navigating Recall Termination and Future Compliance for Consumer Health Products
The FDA's termination of recall D-0783-2020 on September 28, 2022, signifies that the agency was satisfied with Idelle Labs' efforts to remove the non-compliant SURE 48 hr Confidence Antiperspirant from the market and address the underlying issues. However, the core problem of an undeclared active ingredient points to potential systemic weaknesses in either the manufacturing process, quality assurance, or labeling control. For companies operating in the global chemical and life sciences industry, this event serves as a critical reminder that compliance extends beyond initial product registration. Procurement directors must implement enhanced due diligence protocols for all finished goods suppliers, demanding comprehensive Certificates of Analysis (CoAs) that are routinely verified through independent laboratory testing. Regulatory affairs heads should review and strengthen their internal Standard Operating Procedures (SOPs) for product release, particularly focusing on the reconciliation of formulation data with final product labeling. Preventing similar mislabeling incidents requires a proactive, multi-layered approach to quality management that encompasses both internal processes and rigorous oversight of external manufacturing partners, thereby safeguarding brand integrity and consumer trust.